Treatment of difficulty or trouble in breathing with Unani medicine Laooq-e-Hulba

An Open-Label, Clinical Validation Study to Evaluate the Efficacy and Safety of Unani Pharmacopoeial Formulation â?? Laooq-e-Hulba in Zeeq un-Nafas (Bronchial Asthma)

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2023/04/051554

Enrollment

110

Registered

2023-04-12

Start date

Unknown

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Laooq-e-Hulba: 5gm twice daily to be taken orally with water after meals for four weeks Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: 1. Subjects of either sex between the age group of 18-65 years. 2. Subjects of Bronchial Asthma for at least 6 months presenting with at least one of the following symptoms: Wheeze Shortness of breath Chest tightness and cough that vary over time and in intensity, Expiratory airflow limitation as suggested by a decreased FEV1 3. Objective evidence for reversible airway obstruction (>=12% and >=200 mL change in FEV1 and/or a 25% and 60 L/min change in PEFR) either spontaneously or after treatment. 4. Subjects with Asthma Control Questionnaire Score > 1.5

Exclusion criteria

Exclusion criteria: 1. FEV1/FVC ratio 2. Pregnant and lactating females 3. Subjects with other Respiratory Tract Infections, tuberculosis and malignancy. 4. Subjects of Presence of chronic cough with expectoration for 2-3 months in each of two successive years. 5. Subjects with co-morbidities, Diabetes Mellitus, Hepatic and Renal Insufficiency 6. Subjects with known interstitial lung disease. 7. Subjects with Tobacco Smoking. 8. Subjects with known chronic obstructive pulmonary disease (COPD) 9. Patient with regular use of oral or systemic corticosteroids for conditions other than Asthma. 10. Subjects who are not willing to participate in the study.

Design outcomes

Primary

Measure	Time frame
Improvement in signs and symptoms of Zeeq un-Nafas (Bronchial Asthma)Timepoint: 4 weeks	—

Secondary

Measure	Time frame
Haematological and biochemical assessment for safety assessment Timepoint: Investigations will be done at 1st week and 4th week.	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026